BIIB

Business Context and Reporting Period

Company: Biogen Idec Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2006
Business Overview: Biogen Idec is a global biotechnology company focused on oncology, neurology, and immunology. Key products include AVONEX (MS), RITUXAN (oncology/RA), ZEVALIN (oncology), and TYSABRI (MS). TYSABRI was voluntarily suspended in February 2005 due to safety concerns (PML) but received FDA and EMEA approval for reintroduction in June 2006, with shipments commencing in July 2006.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss vs. Profit: The company reported a net loss of $170.6 million for the quarter and $47.6 million for the six months ended June 30, 2006, compared to net income of $34.5 million and $78.0 million in the prior year periods. This reversal is primarily due to significant non-cash charges.
• Acquired In-Process R&D (IPR&D): A one-time charge of $330.5 million was recorded in Q2 2006 related to the acquisitions of Fumapharm ($207.4 million) and Conforma ($123.1 million). These amounts were expensed immediately as the projects had not reached technological feasibility.
• Revenue Growth: Total revenues increased 9% year-over-year for the quarter and 6.5% for the six-month period. Product sales grew to $436.1 million (Q2) and $842.6 million (6M), driven by AVONEX and RITUXAN copromotion profits.
• Share-Based Compensation: Adoption of SFAS 123(R) on January 1, 2006, resulted in a significant increase in share-based compensation expense ($41.6 million in Q2 and $65.6 million for the six months), reducing net income by approximately $19.6 million for the six-month period compared to prior accounting methods.
• Gain on Settlement: A $34.2 million gain was recognized in Q2 2006 related to the settlement of a pre-existing license agreement with Fumapharm upon acquisition.

Guidance, Outlook, and Risks

• TYSABRI Reintroduction: Following FDA and EMEA approval in June 2006, the company began shipping TYSABRI in July 2006. Management expects to recognize revenue from TYSABRI sales beginning in the third quarter of 2006. However, sales are subject to strict risk management protocols (TOUCH Prescribing Program) due to PML risks.
• Acquisition Integration: The company expects to incur additional costs to complete development of acquired assets (BG-12 from Fumapharm and CNF2024 from Conforma), with estimated revenues not expected until 2011 and 2012, respectively.
• Legal and Regulatory Risks: The company faces ongoing litigation regarding TYSABRI safety (class actions, SEC investigation) and RITUXAN marketing practices (False Claims Act, Medicaid reimbursement). Outcomes are uncertain and could result in significant costs.
• Manufacturing: Construction of a large-scale biologic manufacturing facility in Hillerod, Denmark, is ongoing. Completion and licensing depend on market acceptance of TYSABRI.
• Accounting Changes: The company adopted SFAS 123(R) for share-based payments, which will continue to impact reported earnings in future periods.

Key Facts for Investor Verification

• TYSABRI Commercialization: Verify actual sales volumes and market penetration of TYSABRI in Q3 and Q4 2006 following the July launch, given the strict prescribing restrictions.
• Acquisition Milestones: Monitor progress on the development of BG-12 (MS) and CNF2024 (oncology) to assess the potential return on the $330.5 million IPR&D write-off.
• Legal Exposure: Track the status of the SEC investigation regarding TYSABRI and the various class-action lawsuits related to TYSABRI safety and RITUXAN marketing to estimate potential liabilities.
• Share-Based Compensation Impact: Review future quarters to understand the ongoing impact of SFAS 123(R) on operating margins and net income.
• Inventory Valuation: Confirm that capitalized inventory costs for TYSABRI ($22.2 million as of June 30, 2006) are being realized through sales and do not require future write-downs.